Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19
Inventors
Ichim, Thomas E • Dixon, Timothy G
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11266707-B2
Publication Date
2022-03-08
Expiration Date
Abstract
Disclosed herein are methods of treating or preventing complications associated with a SARS-CoV-2 infection, comprising: administration of a combination comprising: a) Green Tea and/or extract thereof; b) Blueberry and/or extract thereof; c) Nigella sativa and/or extract thereof; and d) broccoli and/or extract thereof in an amount and frequency sufficient to treat or prevent complications associated with said SARS-CoV-2 infection.
Core Innovation
The invention relates to a method of treating or preventing complications associated with a SARS-CoV-2 infection by administering a combination comprising green tea and/or extract thereof, blueberry and/or extract thereof, Nigella sativa and/or extract thereof, and broccoli and/or extract thereof. The combination is provided in an amount and frequency sufficient to treat or prevent the complications.
The background problem addressed is that, at the time, there is a lack of effective double-blind interventions for COVID-19 and the progression of COVID-19 is associated with complications that include viral establishment and viral replication followed by inflammatory and immune dysregulation. The description frames SARS-CoV-2 infection complications as involving outcomes such as ARDS and cytokine storm pathology, including inflammatory mediators and signaling pathways.
The invention’s rationale is that the multi-component blend provides complementary mechanisms. It includes NK-cell/IFN-mediated susceptibility early in infection to address viral establishment and replication, and it includes suppression of viral proliferation. It further emphasizes dampening inflammatory/cytokine-storm/ARDS pathology, including TNF-alpha and IL-6 pathway involvement and signaling such as NF-kappaB and TLR4, with mention of related antioxidant/inflammatory modulation pathways such as Nrf2/ARE and effects connected to endothelial activation/coagulopathy and inflammatory marker reduction.
Claims Coverage
The partial claim set includes one independent claim. The independent claim covers a method of treating or preventing SARS-CoV-2 infection complications through administration of a four-component combination (green tea, blueberry, Nigella sativa, and broccoli) in an amount and frequency sufficient to treat or prevent the complications, with multiple dependent claim refinements describing specific bioactives and mechanistic and biomarker limitations.
Combination for treating or preventing SARS-CoV-2 complications
Administering a combination comprising green tea and/or extract thereof, blueberry and/or extract thereof, Nigella sativa and/or extract thereof, and broccoli and/or extract thereof in an amount and frequency sufficient to treat or prevent complications associated with the SARS-CoV-2 infection.
Named bioactive compounds in the combination
Specifying that the green tea, blueberry, Nigella Sativa, and broccoli extracts are epigallocatechin-3-gallate, pterostilbene, thymoquinone, and sulforaphane (or analogues), respectively.
Enhancing natural killer cell activity to inhibit viral establishment
Inhibiting viral establishment into a host by enhancing natural killer cell activity.
Dose and frequency sufficient to inhibit viral replication
Administering the specified combination to a host at a dosage and frequency sufficient to inhibit viral replication.
ARDS associated with enhanced monocytic accumulation in alveolar space
Providing that ARDS is associated with enhanced monocytic accumulation in the alveolar space.
Selecting inflammatory markers from a defined list
Characterizing inflammatory-marker reduction by selecting inflammatory markers from a defined list including CD40L, Eotaxin, fibrinogen, and multiple named cytokines and proteins such as IL-6, CRP, and MPO.
Across the independent claim and its refinements, the claimed coverage centers on administering a four-component green tea/blueberry/Nigella sativa/broccoli combination for treating or preventing SARS-CoV-2 complications, with dependent claims further specifying named bioactives, mechanistic limitations related to NK-cell activity and viral establishment and replication, and narrowing of ARDS and inflammatory-marker effects through immune-cell accumulation and enumerated inflammatory markers.
Stated Advantages
Treating or preventing complications associated with a SARS-CoV-2 infection.
Inhibiting viral establishment into a host by enhancing natural killer cell activity.
Inhibiting viral replication.
Decreasing ARDS propensity associated with enhanced monocytic accumulation in the alveolar space.
Reducing inflammatory markers by selecting markers from a defined list.
Documented Applications
A nutraceutical intervention concept for preventing or treating SARS-CoV-2 infection complications, including ARDS and cytokine-storm pathology, by administering the described multi-component blend.
Interested in licensing this patent?